Tags

Type your tag names separated by a space and hit enter

[Cytokine secretion in whole blood of healthy subjects following oral administration of Urtica dioica L. plant extract].
Arzneimittelforschung. 1996 Sep; 46(9):906-10.A

Abstract

Twenty healthy volunteers ingested for 21 days 2 capsules b.i.d. of an IDS 23/1 containing nettle leaf extract (Rheuma-Hek). Before and after 7 and 21 days the basal and the lipopolysaccharide (LPS) stimulated tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta) and interleukin-6 (IL-6) concentrations were measured ex vivo. In vitro the effects of IDS 23/1 on the release of these cytokines were determined. Additionally basal interleukin-4 (IL-4) and interleukin-10 (IL-10) levels were recorded. Orally taken the test drug has ex vivo no effect on basal levels of TNF-alpha, IL-1 beta, IL-4, IL-6 or IL-10 which were always below detection limits. After 7 and 21 days ingestion ex vivo a decrease of LPS stimulated TNF-alpha release of 14.6 and 24.0%, respectively, was observed. IL-1 beta was reduced for 19.2 and 39.3%. In vitro IDS 23/1 added to whole blood resulted in an exceeded inhibition of LPS stimulated TNF-alpha and IL-1 beta secretion which correlated with the duration of the drug ingestion. Using the highest tested IDS 23/1 concentration the inhibition reached 50.5 (day 0) to 79.5% (day 21) for TNF-alpha and 90.0 (day 0) to 99.2% (day 21) for IL-1 beta, respectively. IDS 23/1 induced a pronounced release of IL-6 in absence of LPS only in vitro. The detected IL-6 concentrations were comparable to those after LPS stimulation, additive effects could not be observed. The absence of detectable IL-6 concentrations in whole blood ex vivo after oral ingestion of the tested drug as well as the differences in the inhibition patterns for TNF-alpha and IL-1 beta ex vivo and ex vivo in vitro suggest that the extract contains different pharmacological effective compounds with varying bioavailabilities.

Authors+Show Affiliations

Strathmann AG & Co., Hamburg.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
English Abstract
Journal Article

Language

ger

PubMed ID

8967906

Citation

Teucher, T, et al. "[Cytokine Secretion in Whole Blood of Healthy Subjects Following Oral Administration of Urtica Dioica L. Plant Extract]." Arzneimittel-Forschung, vol. 46, no. 9, 1996, pp. 906-10.
Teucher T, Obertreis B, Ruttkowski T, et al. [Cytokine secretion in whole blood of healthy subjects following oral administration of Urtica dioica L. plant extract]. Arzneimittelforschung. 1996;46(9):906-10.
Teucher, T., Obertreis, B., Ruttkowski, T., & Schmitz, H. (1996). [Cytokine secretion in whole blood of healthy subjects following oral administration of Urtica dioica L. plant extract]. Arzneimittel-Forschung, 46(9), 906-10.
Teucher T, et al. [Cytokine Secretion in Whole Blood of Healthy Subjects Following Oral Administration of Urtica Dioica L. Plant Extract]. Arzneimittelforschung. 1996;46(9):906-10. PubMed PMID: 8967906.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Cytokine secretion in whole blood of healthy subjects following oral administration of Urtica dioica L. plant extract]. AU - Teucher,T, AU - Obertreis,B, AU - Ruttkowski,T, AU - Schmitz,H, PY - 1996/9/1/pubmed PY - 1996/9/1/medline PY - 1996/9/1/entrez SP - 906 EP - 10 JF - Arzneimittel-Forschung JO - Arzneimittelforschung VL - 46 IS - 9 N2 - Twenty healthy volunteers ingested for 21 days 2 capsules b.i.d. of an IDS 23/1 containing nettle leaf extract (Rheuma-Hek). Before and after 7 and 21 days the basal and the lipopolysaccharide (LPS) stimulated tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta) and interleukin-6 (IL-6) concentrations were measured ex vivo. In vitro the effects of IDS 23/1 on the release of these cytokines were determined. Additionally basal interleukin-4 (IL-4) and interleukin-10 (IL-10) levels were recorded. Orally taken the test drug has ex vivo no effect on basal levels of TNF-alpha, IL-1 beta, IL-4, IL-6 or IL-10 which were always below detection limits. After 7 and 21 days ingestion ex vivo a decrease of LPS stimulated TNF-alpha release of 14.6 and 24.0%, respectively, was observed. IL-1 beta was reduced for 19.2 and 39.3%. In vitro IDS 23/1 added to whole blood resulted in an exceeded inhibition of LPS stimulated TNF-alpha and IL-1 beta secretion which correlated with the duration of the drug ingestion. Using the highest tested IDS 23/1 concentration the inhibition reached 50.5 (day 0) to 79.5% (day 21) for TNF-alpha and 90.0 (day 0) to 99.2% (day 21) for IL-1 beta, respectively. IDS 23/1 induced a pronounced release of IL-6 in absence of LPS only in vitro. The detected IL-6 concentrations were comparable to those after LPS stimulation, additive effects could not be observed. The absence of detectable IL-6 concentrations in whole blood ex vivo after oral ingestion of the tested drug as well as the differences in the inhibition patterns for TNF-alpha and IL-1 beta ex vivo and ex vivo in vitro suggest that the extract contains different pharmacological effective compounds with varying bioavailabilities. SN - 0004-4172 UR - https://www.unboundmedicine.com/medline/citation/8967906/[Cytokine_secretion_in_whole_blood_of_healthy_subjects_following_oral_administration_of_Urtica_dioica_L__plant_extract]_ L2 - https://antibodies.cancer.gov/detail/CPTC-IL6-1 DB - PRIME DP - Unbound Medicine ER -